We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Fructooligosaccharides (short-chain FOS / oligofructose)
Short-chain FOS is a distinct prebiotic from chicory inulin, not a synonym for it — same trial, same 10 g dose, and FOS was bifidogenic where long-chain inulin was not. It also tolerates to half the dose, is a FODMAP, and the only dedicated IBS trial was negative.
What the evidence says
Fructooligosaccharides appears to help in 3 of 3 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1999–2025 with a typical study size of 64 participants.
Based on 11 studies · 3 meta-analyses · 8 RCTs · 3,673 total participants
Confidence
High confidenceWhat the studies found
By outcome
The bifidogenic effect is meta-analytically established and dose-related, which is genuinely more than most prebiotics can show. Everything above that is weak or negative: the only dedicated IBS trial was negative, the head-to-head against inulin found no glycaemic benefit where inulin had one, the tolerance ceiling is half of inulin's, and the calcium claim rests on a 12-subject 9-day study reporting one-sided significance.
18 trials ongoing or recruiting · 82 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for Fructooligosaccharides, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for Fructooligosaccharides meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
Not authorised by EFSA
“Inulin/oligofructose enhances calcium absorption”
“Chicory oligofructose contributes to your body's natural defences”
“Inulin/oligofructose from chicory inulin/ oligofructose enhances calcium absorption”
“Oligofructose-enriched inulin (specific selection of short & long chains) from chicory -increased bone mineral density; -increased bone strength”
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
FOS and inulin are routinely sold and written about interchangeably, and the trial record says they are not the same thing.
In a dose-response study whose head-to-head screening phase randomised just 64 volunteers across eight groups of 8 to seven non-digestible carbohydrates and placebo at an identical 10 g/day, short-chain FOS was bifidogenic (P=0.008) while long-chain inulin was NOT — the clearest single demonstration that chain length matters here.
The distinction is degree of polymerisation: short-chain FOS is a few fructose units long and ferments fast and early in the colon, while chicory inulin runs to much longer chains and ferments more slowly and further down. That difference cuts both ways.
A gastrointestinal tolerance study found native inulin was well tolerated to 10 g/day while oligofructose was tolerated only to 5 g/day — half the ceiling.
And in a 131-person head-to-head trial, inulin improved oral glucose tolerance and fasting insulin in overweight and obese participants while FOS did not improve glycaemic metrics in either group; FOS's only significant finding there was a reduction in homocysteine.
So FOS is worth separating out, but not because it is better.
What FOS does have is a clean bifidogenic record: a meta-analysis of eight trials found FOS raised Bifidobacterium (WMD 0.579), with larger effects at doses above 5 g and durations beyond 4 weeks, and no excess gastrointestinal adverse events across the pooled trials.
Individual dose-finding work puts the sweet spot around 10 g/day, above which excess flatus becomes significantly more frequent and more intense at 20 g. Beyond bifidobacteria the clinical evidence is thin and partly negative.
The dedicated IBS trial — 20 g/day, 96 patients, 12 weeks — found symptoms improved MORE in the placebo group at 4-6 weeks, and no significant difference by the end. A weight-loss trial at 21 g/day produced about 1 kg over 12 weeks alongside lower ghrelin and higher peptide YY, with no change in GLP-1.
The calcium-absorption claim rests on a 12-boy, 9-day crossover reporting one-sided significance, which is not a foundation for a general mineral-absorption claim. And FOS is a FODMAP, so the same caution that applies to GOS applies here.
Short-chain FOS is only a few fructose units long, so it is fermented rapidly and early in the colon. A meta-analysis of eight trials confirms the resulting increase in Bifidobacterium, larger at doses above 5 g/d and durations beyond 4 weeks, with no other bacterial genus significantly affected.
The one head-to-head that tested seven non-digestible carbohydrates at the same 10 g/d dose found short-chain FOS bifidogenic and long-chain inulin not — though on only 8 subjects per arm. That is why FOS warrants a separate entry from inulin, and also why the two behave differently on tolerance and on glycaemia.
In overweight and obese adults, 21 g/d lowered the ghrelin area under the curve and raised peptide YY alongside reduced self-reported calorie intake. Plasma active GLP-1 was NOT affected — a common claim this trial does not support.
How Fructooligosaccharides works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
The dedicated trial was negative — at 20 g/d, symptoms improved more on placebo at 4-6 weeks. FOS is also a FODMAP, and the functional-bowel meta-analysis found inulin-type fructans worsened flatulence. There is no evidential case for FOS in IBS.
These are not interchangeable. If the goal is glycaemic control in overweight or obesity, the head-to-head trial favours inulin, which improved OGTT glucose and fasting insulin where FOS improved neither. If the goal is bifidobacteria at a 10 g dose, the seven-carbohydrate comparison favours FOS, on 8 subjects per arm.
The only adolescent data cited here is a 12-boy, 9-day calcium-absorption crossover reporting one-sided significance. It does not support giving FOS to adolescents for bone health.
No trial of supplemental FOS in pregnancy or lactation is cited here. Not established either way.
Not a drug-level interaction — the effect is additive fermentation. Lactulose is itself a non-digestible, colonically fermented sugar, so taken alongside FOS the two fermentable loads add together and produce more flatus, bloating and distension than either alone. Do not start both at once, and keep FOS at or below 10 g/day: excess flatus was significantly more frequent and more intense at 20 g/day.
Tip: Keep to 10 g/day or below — excess flatus was significantly more frequent and more intense at 20 g/d than at 0, 2.5 or 5 g/d
Tip: Not cleanly dose-linear: one dose-response study found bloating more intense at 2.5-5 g/d than at 7.5-10 g/d, so a dose reduction is worth trying but is not guaranteed to help
Tip: These were the symptoms tracked in the IBS trial at 20 g/d; reduce to 5-10 g/day
Fructooligosaccharides has an evidence score of 4.5/10 — emerging evidence based on 53 indexed studies, including 3 meta-analyses. Short-chain FOS is a distinct prebiotic from chicory inulin, not a synonym for it — same trial, same 10 g dose, and FOS was bifidogenic where long-chain inulin was not. It also tolerates to half the dose, is a FODMAP, and the only dedicated IBS trial was negative. Representative study: PMID 30949662.
The commonly studied dose of Fructooligosaccharides is 5-10 g/day. The meta-analysis found larger bifidogenic effects above 5 g/d, and the dose-finding study concluded 10 g/d was the optimal well-tolerated dose. Do not extrapolate upward: at 20 g/d excess flatus became significantly more frequent and more intense. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Fructooligosaccharides is with meals. Take it with food. The dose-finding trials administered FOS in two divided oral doses with the usual diet.
Fructooligosaccharides is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are excess flatus, bloating, abdominal distension, rumbling and pain. Use caution if any of these apply to you: Strict low-FODMAP diet — FOS is one of the oligosaccharides that diet removes; Hereditary fructose intolerance.
Caffeine
Likely helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — one of the most proven ergogenic aids.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Peppermint Oil
Mostly mechanism / observationalEnteric-coated peppermint oil is one of the better-evidenced botanicals in gastroenterology — multiple meta-analyses of randomized trials show it relieves global symptoms and abdominal pain in irritable bowel syndrome (IBS), with smaller but consistent signals for functional dyspepsia (combined with caraway oil). It is an antispasmodic, not a cure.
Lactoferrin
Mostly mechanism / observationalA multifunctional iron-binding glycoprotein from milk with broad antimicrobial, anti-inflammatory, and immune-modulating properties.
Explore: Best supplements for Body HealthBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 11 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research